Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1268439 | 0.90 | TP53 (0.34) | TP53LMNAENPP2POLBKMT2A | |
| SCHEMBL1269529 | 0.85 | PROKR1 (0.40) | TP53LMNAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL1268426 | 0.81 | LMNA (0.37) | TP53LMNATSHRPOLB | |
| SCHEMBL1268371 | 0.80 | PROKR1 (0.42) | TP53LMNANPSR1ALDH1A1CYP1A2 | |
| SCHEMBL1269325 | 0.71 | SMN1; SMN2 (0.40) | LMNAALDH1A1POLBKMT2AHTT | |
| SCHEMBL1269553 | 0.69 | SMN1; SMN2 (0.50) | TP53LMNANPSR1ALDH1A1POLB | |
| SCHEMBL1269185 | 0.69 | TP53 (0.36) | TP53TSHRNPSR1ALDH1A1POLB | |
| SCHEMBL1269223 | 0.69 | HTR6 (0.41) | — | |
| SCHEMBL30444701 | 0.63 | CYP17A1 (0.44) | TP53LMNAALDH1A1POLB | |
| SCHEMBL20574134 | 0.63 | CYP17A1 (0.44) | TP53LMNAALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | GSK3B, GSK3A, GSKIP | TP53 1224/4885LMNA 1199/4885TSHR 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.